KGX103

KGX103 is a preclinical-stage procytokine immunotherapy designed for the treatment of solid tumors and advanced neoplasms. It is engineered to be conditionally activated within the tumor microenvironment (TME), where it acts as a powerful agonist that rescues exhausted CD8+ T cells and natural killer (NK) cells, promoting their proliferation, activation, and long-term survival. By re-invigorating these immune effector cells in the TME, KGX103 has the potential to convert immunologically "cold" tumors into "hot" tumors that are more responsive to checkpoint inhibitors such as anti-PD-L1 therapies. The molecule features an extended half-life domain for improved pharmacokinetics and utilizes tumor protease activation for enhanced tumor selectivity[2][3][9]. Developed by Shanghai Kangkang Biopharmaceutical Co., Ltd., KGX103 remains in preclinical development with no reported clinical trial data or regulatory approvals as of June 2025[1][2].